These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30888566)

  • 1. Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis.
    Hu C; Wu C; Yang E; Huang H; Xu D; Hou Y; Zhao J; Li M; Xu Z; Zeng X; Wang Q
    Clin Rheumatol; 2019 Aug; 38(8):2181-2187. PubMed ID: 30888566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.
    Fathi M; Barbasso Helmers S; Lundberg IE
    J Intern Med; 2012 Jun; 271(6):589-97. PubMed ID: 21950266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease.
    Wang Y; Chen S; Lin J; Xie X; Hu S; Lin Q; Zheng K; Du G; Huang X; Zhang G; Gargani L; Matucci-Cerinic M; Furst DE
    Rheumatology (Oxford); 2020 Aug; 59(8):2024-2029. PubMed ID: 31794028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker.
    Hanaoka M; Katsumata Y; Kawasumi H; Kawaguchi Y; Yamanaka H
    Mod Rheumatol; 2019 Jul; 29(4):625-632. PubMed ID: 30484723
    [No Abstract]   [Full Text] [Related]  

  • 5. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
    Ye Y; Fu Q; Wang R; Guo Q; Bao C
    J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum KL-6 in adult patients with polymyositis and dermatomyositis.
    Kubo M; Ihn H; Yamane K; Kikuchi K; Yazawa N; Soma Y; Tamaki K
    Rheumatology (Oxford); 2000 Jun; 39(6):632-6. PubMed ID: 10888708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.
    Lee JS; Lee EY; Ha YJ; Kang EH; Lee YJ; Song YW
    Arthritis Res Ther; 2019 Feb; 21(1):58. PubMed ID: 30764869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
    Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
    [No Abstract]   [Full Text] [Related]  

  • 10. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
    Chen F; Shu XM; Wang DX; Xie Y; Wang GC
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
    Ihn H; Asano Y; Kubo M; Yamane K; Jinnin M; Yazawa N; Fujimoto M; Tamaki K
    Rheumatology (Oxford); 2002 Nov; 41(11):1268-72. PubMed ID: 12421999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
    Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
    Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum KL-6 level as a biomarker of interstitial lung disease in childhood connective tissue diseases: a pilot study.
    Kilinc AA; Arslan A; Yildiz M; Kucur M; Adrovic A; Barut K; Sahin S; Cokugras H; Kasapcopur O
    Rheumatol Int; 2020 Oct; 40(10):1701-1706. PubMed ID: 31784789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
    Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
    Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical value of KL-6 for predicting the occurrence and severity of connective tissue disease-associated interstitial lung disease is not affected by CTD type or treatment.
    Xing H; Liang H
    PeerJ; 2024; 12():e17792. PubMed ID: 39131623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study.
    Oguz EO; Kucuksahin O; Turgay M; Yildizgoren MT; Ates A; Demir N; Kumbasar OO; Kinikli G; Duzgun N
    Clin Rheumatol; 2016 Mar; 35(3):663-6. PubMed ID: 26758437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
    Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
    Sato S; Uejima Y; Nanbu M; Suganuma E; Takano T; Tanaka R; Kabuki T; Oguma E; Oh-Ishi T; Kawano Y
    Mod Rheumatol; 2017 Jul; 27(4):652-656. PubMed ID: 27588444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi I; Ono S; Kawamura N; Okano M; Miyazawa K; Shibuya H; Kobayashi K
    J Pediatr; 2001 Feb; 138(2):274-6. PubMed ID: 11174630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.